肿瘤药学2016，Vol.6Issue(2)：136-141,6.DOI:10.3969/j.issn.2095-1264.2016.02.10
GSTP1/RRM1基因多态性与 GP 方案治疗非小细胞肺癌的疗效及毒性的相关性研究
Correlation of GSTP1/RRM1 Gene Polymorphisms with the Clinical Efficacy and Toxicity of GP Programs in the Treatment of Non-small Cell Lung Cancer
摘要
Abstract
Objective To investigate the correlation of the polymorphisms of glutathione S-transferase P1 (GSTP1) gene A105G and ribonucleotide reductase subunit 1 (RRM1) gene C37A-T524C with the clinical efficacy and toxicity of GP programs in the treatment of Non-small Cell Lung Cancer(NSCLC). Methods Sanger sequencing method was used to detect the gene polymorphism of GSTP1 A105G and RRM1 C37A-T524C in peripheral blood of 47 cases of NSCLC patients who were confirmed by pathology. All patients were treated by chemotherapy of GP programs. Their clinical curative effects (RECIST) and side effects were evaluated after two cycles of treatment. Then the correlation of GSTP1 A105G and RRM1 C37A-T524C polymorphism with the clinical curative effects, toxic and side effects were analyzed. Results The genotype frequency distribution of GSTP1 A105G loci G/G, A/G and A/A was 4.3%, 31.9% and 63.8% respectively. No significant difference was found in the GSTP1 A105G gene frequency distribution be-tween chemotherapy-sensitive group and non-sensitive group (P> 0.05). The frequency of RRM1 C37A-T524C high ef-ficacy and non-high efficacy genotype was 36.2% and 63.8% respectively. The RRM1C37A-T524C high efficacy genotype ratio (51.17%) of chemotherapy-sensitive group was significantly higher than that of the non-sensitive group (17.39%) (P = 0.0087). According to the joint detection results of gene polymorphism of GSTP1 A105G and RRM1 C37A-T524C, there were 6 types, A (A/A+ high efficient genotypes), B (A/G + high efficient genotype), C (G/G + high efficient genotype), D (A/A +non- high efficient genotype), E (A/G + non-high efficient genotype), F (G/G +non- high efficient genotype), and their frequencies were respectively 29.8%, 6.4%, 0%, 34.0%, 25.5% and 4.3%. The type A genes was mostly distributed in the chemotherapy-sensitive group (45.83%), more than in the non-sensitive chemotherapy group (13.04%) (P= 0.0088). However, there was no statistically significant difference in the incidence of toxic and side effects of GP regime between different genome types (P>0.05). Conclusion Compared with the detection of single gene polymorphism, joint detection of polymorphism of GSTP1A105G and RRM1C37A-T524C in peripheral blood was more helpful for patients to accept GP chemotherapy. Especially, RRM1 gene polymorphism might be used as important biological markers to predict the curative effect of GP regime for NSCLC patients.关键词
非小细胞肺癌/谷胱甘肽 S 转移酶 P1/核糖核苷酸还原酶亚单位 1/基因多态性/吉西他滨/顺铂/化疗敏感性/ 化疗毒副反应Key words
Non-small cell lung cancer/Glutathione S-transferase P1/Ribonucleotide reductase subunitM1/Genetic polymorphism/Gemcitabine/cisplatin/Chemotherapy sensitivity/toxic and side reaction of chemotherapy分类
医药卫生引用本文复制引用
袁志军,周文武,刘维,赵瑾,吴尉,何奕,杨烁,苏婧,罗以..GSTP1/RRM1基因多态性与 GP 方案治疗非小细胞肺癌的疗效及毒性的相关性研究[J].肿瘤药学,2016,6(2):136-141,6.基金项目
湖南省科技厅科技计划课题项目(编号06JT3008)；湖南省保健专项资金科研课题项目(编号B2012-06)；国家外专局专项基金资助项目。 （编号06JT3008）
